IXICO end with strong financial year, with focus on ageing population and need for new treatments

Name: IXICO end with strong financial year, with focus on ageing population and need for new treatments
Uploaded: 2021-10-18T10:16:00Z
Description: IXICO end with strong financial year, with focus on ageing population and need for new treatments

Proactive Published 18/10/2021

Share X in f @

IXICO PLC (AIM:IXI, OTC:PHYOF) (AIM:IXI, OTC:PHYOF) IXICO PLC's (LON:IXI) CEO Giulio Cerroni joins Proactive London's Katie Pilbeam to discuss the revenues in the year to end 30 September 2021 which he says will beat market forecasts even with the halting of a Huntington’s disease trial by its largest customer.

Full-year revenue will be £9.2mln (2020: £9.5mln) compared to forecasts of £8.7mln, which had been reduced after the Huntington trial news.

The end of that trial also wiped £7.1mln from the order book, which at the year-end was £18.8mln (£21.7mln).